Skip to main content

Hologic to Complete Third Wave Purchase Today

NEW YORK (GenomeWeb News) – Hologic said that it would complete its $580 million acquisition of Third Wave Technologies after the close of business today.
 
The Bedford, Mass.-based medical imaging and diagnostics firm said that as of midnight last night, Third Wave shareholders had tendered 47,968,050 shares of the firm, representing 95.8 percent of Third Wave’s outstanding stock. Hologic paid $11.25 per share for Third Wave’s stock, which will cease trading on the Nasdaq after today.
 
The acquisition, which was announced in early June, will provide Hologic with complementary products targeted to the women’s health and diagnostics market. Hologic sells the ThinPrep pap test, while Madison, Wis.-based Third Wave recently filed for US Food and Drug Administration clearance for two molecular diagnostic tests for human papillomavirus.
 
 

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.